GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
    • Reports
      • GHTM
      • Scientific Advisory Board
      • FCT
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
Home / Articles / New / GHTM Researchers’ breakthrough to fight Mycobacterium tuberculosis’ drug resistance

GHTM Researchers’ breakthrough to fight Mycobacterium tuberculosis’ drug resistance

October 7, 2021

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is one of the deadliest infectious diseases worldwide, leading to 10 million human cases and 1.4 million associated deaths in 2019. Most cases are found in Asia, Africa, and Western Pacific regions. TB drug resistance is one of the major threats to control the disease, and its expansion is exhausting treatment options, including the recent anti‑TB medications: bedaquiline (BDQ), delamanid (DLM) and pretomanid (PTM). To improve the understanding of the causative mechanisms of resistance for these drugs, this research focused in 12 M. tuberculosis’ genes, being the genetic diversity of nine of them, strongly linked to resistance, investigated across more than 33,000 isolates. The result of this study is a comprehensive mutational catalogue for BDQ and DLM/PTM associated genes that will assist with establishing associations with phenotypic resistance, which can lead to better treatment outcomes.

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid

 

Phylogenetic trees of high frequency mutations.

Track a shows the clades formed by isolates harbouring the same phylogenetic-related mutations; track b shows the convergent mutations that have arisen in more than one clade; track c shows the resistance phenotype. Branches are coloured by lineage as per legend.

Bedaquiline candidate genes.

Tuberculosis' drug resistance - Genetic diversity of candidate loci linked to Mtuberculosis resistance

 

Delamanid and pretomanid candidate genes.

Tuberculosis' drug resistance - Genetic diversity of candidate loci linked to MtuberculosisFig3

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to print (Opens in new window) Print

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

 

Loading Comments...
 

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok